Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

(2021) Thierry Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review

(2020) Maria Lorenzi et al.   Journal of Oncology

LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET

(2020) A. Oaknin et al.   ANNALS OF ONCOLOGY

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

(2020) Ana Oaknin et al.   JAMA Oncology

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

(2019) Fabrice Barlesi et al.   Journal of Thoracic Oncology

Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions

(2019) Bellinda L King-Kallimanis et al.   Clinical Trials

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

(2019) C Luchini et al.   ANNALS OF ONCOLOGY

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

(2019) Pengfei Zhao et al.   Journal of Hematology & Oncology

Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop

(2018) Paul G. Kluetz et al.   VALUE IN HEALTH

Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker

(2018) Floor J. Backes et al.   CANCER

Patient‐Reported Outcomes with PD‐1/PD‐L1 Inhibitors for Advanced Cancer: A Meta‐Analysis

(2018) Tomohiro F. Nishijima et al.   ONCOLOGIST

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

(2018)   Journal for ImmunoTherapy of Cancer

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

(2017) Julie R Brahmer et al.   LANCET ONCOLOGY

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity

(2017) Gloria Mittica et al.   Oncotarget

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms

(2016) P. G. Kluetz et al.   CLINICAL CANCER RESEARCH

Microsatellite Instability as a Biomarker for PD-1 Blockade

(2016) J. C. Dudley et al.   CLINICAL CANCER RESEARCH

Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade

(2016) Valerie Lee et al.   ONCOLOGIST

Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

(2015) Brooke E. Howitt et al.   JAMA Oncology

Quality of Life Research in Endometrial Cancer

(2014) Jessica N. McAlpine et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Increased incidence and improved survival in endometrioid endometrial cancer diagnosed since 1989 in The Netherlands: a population based study

(2012) D. Boll et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P

(2009) Don S. Dizon et al.   JOURNAL OF CLINICAL ONCOLOGY